These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8088172)

  • 1. Immunosuppression and leukocytes.
    Jensen LS
    Curr Stud Hematol Blood Transfus; 1994; (60):64-74. PubMed ID: 8088172
    [No Abstract]   [Full Text] [Related]  

  • 2. Disseminated intravascular coagulation reaction to granulocytes in a patient with human leukocyte antigen sensitisation.
    Scott A; Warner P; Delaney M
    Transfus Med; 2019 Aug; 29(4):287-289. PubMed ID: 31090120
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukoreduction just doesn't "take away" immunogenic leukcocytes, it creates an immunosuppressive leukocyte dose.
    Semple JW; Freedman J
    Vox Sang; 2002 Aug; 83 Suppl 1():425-7. PubMed ID: 12617180
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs.
    Lane TA
    Arch Pathol Lab Med; 1994 Apr; 118(4):392-404. PubMed ID: 8166589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypotensive reactions associated with transfusion of bedside leukocyte-reduction filtered blood products in heart transplanted patients.
    Lavee J; Paz Y
    J Heart Lung Transplant; 2001 Jul; 20(7):759-61. PubMed ID: 11448805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes.
    Lee JH; Klein HG
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):585-600. PubMed ID: 11102278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An experimental model for preventing alloimmunization against platelet transfusions by pretreatment with antibody-coated cells.
    Süsal C; Terness P; Opelz G
    Vox Sang; 1990; 59(4):209-15. PubMed ID: 2293460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Leukocyte depletion of labile blood products].
    Gerota J; Cavalier J; Masse M; Waller W; Bidet ML
    Rev Fr Transfus Immunohematol; 1987; 30(2):109-34. PubMed ID: 3659740
    [No Abstract]   [Full Text] [Related]  

  • 9. Measures to prevent TRALI.
    Wendel S; Biagini S; Trigo F; Fontão-Wendel R; Taaning E; Jørgensen J; Riisom K; Krusius T; Koskinen S; Kretschmer V; Karger R; Lawlor E; Okazaki H; Charlewood R; Brand A; Solheim BG; Flesland O; Letowska M; Zupanska B; Muñiz-Diaz E; Nogués N; Senn M; Mansouri-Taleghani B; Chapman CE; Massey E; Navarrete C; Stainsby D; Win N; Williamson LM; Kleinman S; Kopko PM; Silva M; Shulman I; Holness L; Epstein JS
    Vox Sang; 2007 Apr; 92(3):258-77. PubMed ID: 17348877
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of leukoconcentrate in the treatment of postoperative suppurative complications in cardiosurgical patients with immunosuppression].
    Kolesov AP; Bykova TV; Shulëva OV; Zhuravlev IuN
    Vestn Khir Im I I Grek; 1985 Aug; 135(8):109-12. PubMed ID: 4060498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte-poor blood components: a purer and safer transfusion product for recipients?
    Rebulla P; Bertolini F; Parravicini A; Sirchia G
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):19-23. PubMed ID: 2134637
    [No Abstract]   [Full Text] [Related]  

  • 12. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
    Vamvakas EC; Blajchman MA
    Blood; 2001 Mar; 97(5):1180-95. PubMed ID: 11222359
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocyte and plasma activation profiles in chronically transfused patients with a history of allergic reactions.
    Fontaine MJ; Shih H; Schubert R; Wong W; Andrews J; Jeng M; Tirouvanziam R
    Transfusion; 2017 Nov; 57(11):2639-2648. PubMed ID: 28880378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wolf in wolf's clothing: is it time to raise the bounty on the passenger leukocyte?
    Klein HG
    Blood; 1992 Oct; 80(8):1865-8. PubMed ID: 1391950
    [No Abstract]   [Full Text] [Related]  

  • 15. Granulocyte transfusion: current status.
    Price TH
    Semin Hematol; 2007 Jan; 44(1):15-23. PubMed ID: 17198843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion-transmitted cytomegalovirus infection.
    Bowden RA
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):155-66. PubMed ID: 7737939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood transfusion and immunosuppression.
    Yomtovian R
    Lancet; 1983 Nov; 2(8358):1090-1. PubMed ID: 6138638
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biological effects of allogenic leukocytes and leukocyte-depleted blood cell products].
    Vásová I; Mayer J
    Vnitr Lek; 1995 Oct; 41(10):713-8. PubMed ID: 8578706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Graft-versus-host reaction following granulocyte transfusion from a normal donor (author's transl)].
    Salfner B; Borberg H; Krüger G; Schumacher K; Siebel E
    Blut; 1978 Jan; 36(1):27-34. PubMed ID: 23879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplant outcome with donor specific buffy-coat and lymphocyte-transfused patients.
    Okazaki H; Takahashi H; Jimbo M; Iguro T; Satoh T; Ishizak M
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1832-3. PubMed ID: 2652595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.